Android app Apple app link

Bluebird bio receives non-binding bid for up to $110.5 million

By Yahoo! Finance   |   1 week ago
Bluebird bio receives non-binding bid for up to $110.5 million

Gene therapy company bluebird bio received a $110.5 million non-binding offer from Ayrmid, boosting shares by 9.8%. The proposal includes an upfront payment of $4.50 per share and additional $6.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.